Unique ID issued by UMIN | UMIN000006836 |
---|---|
Receipt number | R000008089 |
Scientific Title | Role of Diabetes in heart failure with preserved left ventricular function |
Date of disclosure of the study information | 2012/03/01 |
Last modified on | 2013/08/02 17:55:37 |
Role of Diabetes in heart failure
with preserved left ventricular function
HFPEF and DM
Role of Diabetes in heart failure
with preserved left ventricular function
HFPEF and DM
Japan |
HFPEF patients with T2DM
Cardiology | Endocrinology and Metabolism |
Others
NO
To elucidate the impact of therapeutic intervention in diabetes on left ventricular diastolic dysfunction and remodeling.
Efficacy
Confirmatory
Explanatory
Phase II
Changes in diastolic left ventricular function assessed by echocardiography (E/e')
Major cardiovascular event
admission due to deteriarated heart failure
changes in serum NT-proBNP value
changes in biomarkers value
changes in delayed enhancement observed each heart detected by cardiac MRI
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
Multicentered cohort study (PROBE study in multicenter)
GroupA; sitagliptin (50/100mg/day) treatment
Data accessment each 6 month for 2 years
Multicentered cohort study (PROBE study in multicenter)
GroupB; therapeutic intervention by remedy except for DPP4 inhibitor.
Data accessment each 6 month for 2 years
40 | years-old | <= |
Not applicable |
Male and Female
Aged 40 or above
Male and female
Ambulatory patient exhibiting his/her HbA1C value is between 6.0% and 8.9%
Left ventricular ejection fraction assessed by echocardiography is more than 50%
Left ventricular diastolic function parameters assessed by echocardiography
satisfy the conditions as follows;
#1 E/e more than 15
#2 E/e between 8 and 15
and
NT-proBNP; more than 900pg/mL
#3 E/e between 8 and 15
or NT-proBNP more than 900pg/mL
and RAd-Ad more than 30msec.
or LAVI more than 40mL/m2
or LVMImore than 110g/m2 in male and 100g/m2 in female
Major cardiovascular events within 3 months after registration
Left ventricular ejection fraction is less than 50 percent
Left ventricular diastolic diameter is more than 49mm
Comorbid atrial fibrillation
Diabetic patients who is treated by DPP-4 inhibitors and/or GLP-1analog
Patients with CKD [eGFR less than 30ml] and ESRD
Type 1 diabetes
Malignancy within 5 years at registration
Uncontrolled cormobid arrhythmia
Uncontrolled cormobid hypertension
Hospitalization within 6 month
Diabetic patients who is treated by insulin
Comorbid severe valuvular heart disease
Comorbid severe ischemic heart disease
Liver injury [ALT/AST values exhibit 5 times higher than normal range]
Pregnancy
50
1st name | |
Middle name | |
Last name | Yasuko K Bando |
Nagoya University Hospital
Department of Cardiology
65 Tsurumai-cho, Showa-ku, Nagoya, Aichi
052-744-2147
1st name | |
Middle name | |
Last name | Yasuko K Bando |
Nagoya University Hospital
Department of Cardiology
65 Tsurumai-cho, Showa-ku, Nagoya, Aichi
052-744-2147
ybando@med.nagoya-u.ac.jp
Department of Cardiology, Nagoya University Graduate School of Medicine
Nagoya University Graduate School of Medicine
Japan
NO
名古屋大学医学部附属病院
2012 | Year | 03 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2011 | Year | 12 | Month | 05 | Day |
2013 | Year | 08 | Month | 05 | Day |
2014 | Year | 03 | Month | 31 | Day |
2011 | Year | 12 | Month | 05 | Day |
2013 | Year | 08 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008089